MX2024003439A - Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático. - Google Patents

Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático.

Info

Publication number
MX2024003439A
MX2024003439A MX2024003439A MX2024003439A MX2024003439A MX 2024003439 A MX2024003439 A MX 2024003439A MX 2024003439 A MX2024003439 A MX 2024003439A MX 2024003439 A MX2024003439 A MX 2024003439A MX 2024003439 A MX2024003439 A MX 2024003439A
Authority
MX
Mexico
Prior art keywords
heteroaromatic
methods
solid tumor
ether compounds
treating solid
Prior art date
Application number
MX2024003439A
Other languages
English (en)
Inventor
Henry Efrem Pelish
Michael Meyers
John R Soglia
Anupong Tangpeerachaikul
Amit M Deshpande
Darlene Noci
James R Porter
Christopher Durant Turner
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of MX2024003439A publication Critical patent/MX2024003439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan métodos para usar un compuesto de éter macrocíclico heteroaromático (por ejemplo, Compuesto 1), o un estereoisómero, o una mezcla de estereoisómeros de este, o una sal farmacéuticamente aceptable de este, para tratar, prevenir o controlar un tumor sólido.
MX2024003439A 2021-10-01 2022-09-30 Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático. MX2024003439A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163251536P 2021-10-01 2021-10-01
US202263357309P 2022-06-30 2022-06-30
PCT/US2022/077364 WO2023056431A1 (en) 2021-10-01 2022-09-30 Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds

Publications (1)

Publication Number Publication Date
MX2024003439A true MX2024003439A (es) 2024-06-21

Family

ID=84246205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003439A MX2024003439A (es) 2021-10-01 2022-09-30 Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático.

Country Status (7)

Country Link
EP (1) EP4408424A1 (es)
KR (1) KR20240095536A (es)
AU (1) AU2022355108A1 (es)
CA (1) CA3231608A1 (es)
IL (1) IL311387A (es)
MX (1) MX2024003439A (es)
WO (1) WO2023056431A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7519463B2 (ja) 2020-05-05 2024-07-19 ヌバレント， インク． ヘテロ芳香族大環状エーテル化学療法剤
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
CA3231813A1 (en) 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2024036097A1 (en) * 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
CN100408100C (zh) 1997-07-29 2008-08-06 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP7519463B2 (ja) * 2020-05-05 2024-07-19 ヌバレント， インク． ヘテロ芳香族大環状エーテル化学療法剤

Also Published As

Publication number Publication date
AU2022355108A1 (en) 2024-04-04
EP4408424A1 (en) 2024-08-07
CA3231608A1 (en) 2023-04-06
WO2023056431A1 (en) 2023-04-06
KR20240095536A (ko) 2024-06-25
IL311387A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
MX2024003439A (es) Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático.
MX2022006986A (es) Inhibidores de kras g12c.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
MX2022007969A (es) Inhibidores de egfr.
MX2022015207A (es) Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus.
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2021013531A (es) Inhibidores de cdk.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
EP4410291A3 (en) Erbb receptor inhibitors
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2023010411A (es) Inhibidores de erbb/btk.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
MX2021012105A (es) Compuestos de pirrol.
MX2024000299A (es) Compuestos antivirales.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021007247A (es) Derivados de rapamicina.
MX2023000943A (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos.
MX2021014458A (es) Compuestos triciclicos.
MX2021009717A (es) Sulfonamidas biciclicas.